PRIMCAT: Predicting the population health economic impact of current and new cancer treatments

Enabling timely and affordable access to new cancer treatments for Australian cancer patients.

Australian cancer patients need timely and affordable access to the best cancer treatments available.

Trends of increasing cancer incidence rates and improving cancer survival outcomes mean increasing demand for cancer treatment in Australia.  Rapid growth in the number, type, combinations and cost of cancer treatments available make for a dynamic and complex treatment landscape.

Australia’s Health Technology Assessment (HTA) agencies, the Pharmaceutical Benefits Advisory Committee (PBAC) and the Medical Services Advisory Committee (MSAC), have raised health policy concerns about uncertainties in the projected number of patients forecast to require treatment at different disease stages.

PRIMCAT will take a data-driven modelling approach to provide 5-year epidemiological estimates of eligible patient populations and quantify the population health economic impact of new cancer treatments for three nominated priority cancers (colorectal cancer, non-small cell lung cancer and melanoma) and two pan-tumour biomarkers.

The work includes mapping current treatment algorithms and determining the actual use of treatments in the real-world, identifying new and emerging cancer treatments likely to be introduced in the next 5 years, identifying the prevalence of gene mutations in the cancer population at which these new treatments are targeted, and developing an online simulation model to predict the health economic impact of listing these new cancer treatments on the PBS and MBS. A significant amount of work is planned to validate the findings with an international panel of experts.

PRIMCAT is led by Professor Maarten IJzerman (UMCCR, MSPGH) in collaboration with Professor Yuting Zhang (Melbourne Institute), Dr. Koen Degeling and Dr. Fanny Franchini (UMCCR, MSPGH), Professor Sallie Pearson (the University of New South Wales), Professor Peter Gibbs (WEHI and Western Health), and Professor Benjamin Solomon, Professor Grant McArthur, Professor Stephen Fox and A/Professor Jayesh Desai (Peter MacCallum Cancer Centre). PRIMCAT will draw on the world-leading expertise of a number of associate investigators, consumer representatives and international peers selected for an advisory board.

Nominated priority cancers:

  • Colorectal Cancer
  • Non-small Cell Lung Cancer
  • Melanoma
  • Pan-tumour biomarkers: MSI-H and NTRK
Maarten IJzerman group

Professor Maarten IJzerman's Cancer Health Services Research group

Analysing real-world costs and results of comprehensive cancer care to inform evidence-based health service interventions and improve outcomes for cancer patients.

Visit the group page

Latest news